{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:22Z","timestamp":1791328882303,"version":"4.3.1"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T00:00:00Z","timestamp":1261440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1038\/nrendo.2009.263","type":"journal-article","created":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T03:50:38Z","timestamp":1261453838000},"page":"83-93","source":"Crossref","is-referenced-by-count":128,"title":["Aldosterone and arterial hypertension"],"prefix":"10.1038","volume":"6","author":[{"given":"Andreas","family":"Tomaschitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Pieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,22]]},"reference":[{"key":"BFnrendo2009263_CR1","unstructured":"WHO. World Health Report 2002: reducing risks, promoting healthy life (WHO, Geneva, 2002)."},{"key":"BFnrendo2009263_CR2","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"DA Calhoun","year":"2008","unstructured":"Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117, e510\u2013e526 (2008).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","volume":"17","author":"P Bramlage","year":"2004","unstructured":"Bramlage, P. et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am. J. Hypertens. 17, 904\u2013910 (2004).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.107.095497","volume":"50","author":"V Perkovic","year":"2007","unstructured":"Perkovic, V., Huxley, R., Wu, Y., Prabhakaran, D. & MacMahon, S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 50, 991\u2013997 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","volume":"52","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis, P. A. & Bakris, G. L. Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol. 52, 1749\u20131757 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2009263_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan, R. S. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 351, 33\u201341 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2009263_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","volume":"116","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson, E. et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116, 984\u2013992 (2007).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR8","doi-asserted-by":"crossref","unstructured":"Kappert, K. & Unger, T. Role of the renin-angiotensin system in hypertension. Hot Topics in Hypertension [ online ], (2008).","DOI":"10.4147\/HTH-080400"},{"key":"BFnrendo2009263_CR9","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1681\/ASN.2005050460","volume":"16","author":"JH Pratt","year":"2005","unstructured":"Pratt, J. H. Central role for ENaC in development of hypertension. J. Am. Soc. Nephrol. 16, 3154\u20133159 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrendo2009263_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1210\/er.2007-0030","volume":"29","author":"JM Connell","year":"2008","unstructured":"Connell, J. M., MacKenzie, S. M., Freel, E. M., Fraser, R. & Davies, E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr. Rev. 29, 133\u2013154 (2008).","journal-title":"Endocr. Rev."},{"key":"BFnrendo2009263_CR11","doi-asserted-by":"publisher","first-page":"14211","DOI":"10.1073\/pnas.2336140100","volume":"100","author":"M Ehrhart-Bornstein","year":"2003","unstructured":"Ehrhart-Bornstein, M. et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl Acad. Sci. USA 100, 14211\u201314216 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2009263_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.RES.40.4.69","volume":"40","author":"W Oelkers","year":"1974","unstructured":"Oelkers, W. et al. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ. Res. 40, 69\u201377 (1974).","journal-title":"Circ. Res."},{"key":"BFnrendo2009263_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0002-9149(00)00728-1","volume":"85","author":"MP Schlaich","year":"2000","unstructured":"Schlaich, M. P., Schobel, H. P., Hilgers, K. & Schmieder, R. E. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am. J. Cardiol. 85, 1199\u20131206 (2000).","journal-title":"Am. J. Cardiol."},{"key":"BFnrendo2009263_CR14","doi-asserted-by":"crossref","unstructured":"Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297, 319\u2013328 (1988).","DOI":"10.1136\/bmj.297.6644.319"},{"key":"BFnrendo2009263_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/sj.jhh.1001603","volume":"17","author":"J Stamler","year":"2003","unstructured":"Stamler, J. et al. INTERMAP: background, aims, design, methods, and descriptive statistics (nondietary). J. Hum. Hypertens. 17, 591\u2013608 (2003).","journal-title":"J. Hum. Hypertens."},{"key":"BFnrendo2009263_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/CS20080207","volume":"117","author":"S Mohan","year":"2009","unstructured":"Mohan, S. & Campbell, N. R. Salt and high blood pressure. Clin. Sci. (Lond.) 117, 1\u201311 (2009).","journal-title":"Clin. Sci. (Lond.)"},{"key":"BFnrendo2009263_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/02813430802661795","volume":"27","author":"E Meland","year":"2009","unstructured":"Meland, E. & Aamland, A. Salt restriction among hypertensive patients: modest blood pressure effect and no adverse effects. Scand. J. Prim. Health Care 27, 97\u2013103 (2009).","journal-title":"Scand. J. Prim. Health Care"},{"key":"BFnrendo2009263_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza, J. L. et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237, 268\u2013275 (1987).","journal-title":"Science"},{"key":"BFnrendo2009263_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/er.2005-0004","volume":"26","author":"JW Funder","year":"2005","unstructured":"Funder, J. W. The nongenomic actions of aldosterone. Endocr. Rev. 26, 313\u2013321 (2005).","journal-title":"Endocr. Rev."},{"key":"BFnrendo2009263_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","volume":"308","author":"C Grossmann","year":"2009","unstructured":"Grossmann, C. & Gekle, M. New aspects of rapid aldosterone signaling. Mol. Cell. Endocrinol. 308, 53\u201362 (2009).","journal-title":"Mol. Cell. Endocrinol."},{"key":"BFnrendo2009263_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00109-008-0323-5","volume":"86","author":"CA Lemarie","year":"2008","unstructured":"Lemarie, C. A., Paradis, P. & Schiffrin, E. L. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J. Mol. Med. 86, 673\u2013678 (2008).","journal-title":"J. Mol. Med."},{"key":"BFnrendo2009263_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","volume":"96","author":"IZ Jaffe","year":"2005","unstructured":"Jaffe, I. Z. & Mendelsohn, M. E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96, 643\u2013650 (2005).","journal-title":"Circ. Res."},{"key":"BFnrendo2009263_CR23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1161\/HYPERTENSIONAHA.108.121269","volume":"52","author":"AC Montezano","year":"2008","unstructured":"Montezano, A. C. & Touyz, R. M. Networking between systemic angiotensin II and cardiac mineralocorticoid receptors. Hypertension 52, 1016\u20131018 (2008).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1161\/ATVBAHA.108.168021","volume":"28","author":"AC Montezano","year":"2008","unstructured":"Montezano, A. C. et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler. Thromb. Vasc. Biol. 28, 1511\u20131518 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2009263_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/01.CIR.104.2.137","volume":"104","author":"E Harada","year":"2001","unstructured":"Harada, E. et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104, 137\u2013139 (2001).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1161\/01.HYP.0000182661.98259.4f","volume":"46","author":"W Chai","year":"2005","unstructured":"Chai, W. et al. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 46, 701\u2013706 (2005).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1161\/01.HYP.0000140771.21243.ed","volume":"44","author":"F Xiao","year":"2004","unstructured":"Xiao, F., Puddefoot, J. R., Barker, S. & Vinson, G. P. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 44, 340\u2013345 (2004).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR28","doi-asserted-by":"publisher","first-page":"E1790","DOI":"10.1152\/ajpendo.00708.2006","volume":"292","author":"C Grossmann","year":"2007","unstructured":"Grossmann, C. et al. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 292, E1790\u2013E1800 (2007).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrendo2009263_CR29","doi-asserted-by":"publisher","first-page":"F314","DOI":"10.1152\/ajprenal.00003.2005","volume":"289","author":"WZ Ying","year":"2005","unstructured":"Ying, W. Z. & Sanders, P. W. Enhanced expression of EGF receptor in a model of salt-sensitive hypertension. Am. J. Physiol. Renal Physiol. 289, F314\u2013F321 (2005).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrendo2009263_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","volume":"97","author":"LJ Min","year":"2005","unstructured":"Min, L. J. et al. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 97, 434\u2013442 (2005).","journal-title":"Circ. Res."},{"key":"BFnrendo2009263_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","volume":"50","author":"M Nagase","year":"2007","unstructured":"Nagase, M., Matsui, H., Shibata, S., Gotoda, T. & Fujita, T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50, 877\u2013883 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR32","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1097\/01.ASN.0000092145.90389.65","volume":"14","author":"C Kitiyakara","year":"2003","unstructured":"Kitiyakara, C. et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J. Am. Soc. Nephrol. 14, 2775\u20132782 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrendo2009263_CR33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","volume":"53","author":"JW Funder","year":"2009","unstructured":"Funder, J. W. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53, 286\u2013290 (2009).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","volume":"103","author":"Y Mizuno","year":"2001","unstructured":"Mizuno, Y. et al. Aldosterone production is activated in failing ventricle in humans. Circulation 103, 72\u201377 (2001).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jsbmb.2005.03.005","volume":"96","author":"T Nishikawa","year":"2005","unstructured":"Nishikawa, T. et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J. Steroid Biochem. Mol. Biol. 96, 309\u2013316 (2005).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"BFnrendo2009263_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/jhh.2008.144","volume":"23","author":"FJ He","year":"2009","unstructured":"He, F. J. & MacGregor, G. A. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J. Hum. Hypertens. 23, 363\u2013384 (2009).","journal-title":"J. Hum. Hypertens."},{"key":"BFnrendo2009263_CR37","first-page":"289","volume":"3","author":"W Nowaczynski","year":"1985","unstructured":"Nowaczynski, W., Oliver, W. J. & Neel, J. V. Serum aldosterone and protein-binding variables in Yanomama Indians: a no-salt culture as compared to partially acculturated Guaymi Indians. Clin. Physiol. Biochem. 3, 289\u2013306 (1985).","journal-title":"Clin. Physiol. Biochem."},{"issue":"Suppl.","key":"BFnrendo2009263_CR38","doi-asserted-by":"publisher","first-page":"I2","DOI":"10.1161\/01.HYP.19.1_Suppl.I2","volume":"19","author":"AC Guyton","year":"1992","unstructured":"Guyton, A. C. Kidneys and fluids in pressure regulation. Small volume but large pressure changes. Hypertension 19 (Suppl.), I2\u2013I8 (1992).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nm.1960","volume":"15","author":"A Machnik","year":"2009","unstructured":"Machnik, A. et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat. Med. 15, 545\u2013552 (2009).","journal-title":"Nat. Med."},{"key":"BFnrendo2009263_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","volume":"47","author":"EL Schiffrin","year":"2006","unstructured":"Schiffrin, E. L. Effects of aldosterone on the vasculature. Hypertension 47, 312\u2013318 (2006).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR41","doi-asserted-by":"publisher","first-page":"H2009","DOI":"10.1152\/ajpheart.00522.2007","volume":"293","author":"SA Cooper","year":"2007","unstructured":"Cooper, S. A. et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 293, H2009\u2013H2023 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrendo2009263_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.pharmthera.2005.10.010","volume":"111","author":"O Skott","year":"2006","unstructured":"Skott, O. et al. Rapid actions of aldosterone in vascular health and disease\u2014friend or foe? Pharmacol. Ther. 111, 495\u2013507 (2006).","journal-title":"Pharmacol. Ther."},{"key":"BFnrendo2009263_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","volume":"458","author":"M Gekle","year":"2009","unstructured":"Gekle, M. & Grossmann, C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch. 458, 231\u2013246 (2009).","journal-title":"Pflugers Arch."},{"key":"BFnrendo2009263_CR44","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","volume":"14","author":"S Arima","year":"2003","unstructured":"Arima, S. et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J. Am. Soc. Nephrol. 14, 2255\u20132263 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrendo2009263_CR45","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","volume":"109","author":"MK Nishizaka","year":"2004","unstructured":"Nishizaka, M. K., Zaman, M. A., Green, S. A., Renfroe, K. Y. & Calhoun, D. A. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 109, 2857\u20132861 (2004).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR46","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1210\/en.2004-0081","volume":"145","author":"N Ahmad","year":"2004","unstructured":"Ahmad, N., Romero, D. G., Gomez-Sanchez, E. P. & Gomez-Sanchez, C. E. Do human vascular endothelial cells produce aldosterone? Endocrinology 145, 3626\u20133629 (2004).","journal-title":"Endocrinology"},{"key":"BFnrendo2009263_CR47","doi-asserted-by":"publisher","first-page":"16281","DOI":"10.1073\/pnas.0707791104","volume":"104","author":"H Oberleithner","year":"2007","unstructured":"Oberleithner, H. et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc. Natl Acad. Sci. USA 104, 16281\u201316286 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2009263_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1748-1716.2006.01574.x","volume":"187","author":"H Oberleithner","year":"2006","unstructured":"Oberleithner, H., Riethmuller, C., Ludwig, T., Hausberg, M. & Schillers, H. Aldosterone remodels human endothelium. Acta Physiol. (Oxf.) 187, 305\u2013312 (2006).","journal-title":"Acta Physiol. (Oxf.)"},{"key":"BFnrendo2009263_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","volume":"51","author":"NJ Brown","year":"2008","unstructured":"Brown, N. J. Aldosterone and vascular inflammation. Hypertension 51, 161\u2013167 (2008).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR50","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.2741\/3361","volume":"14","author":"LJ Ma","year":"2009","unstructured":"Ma, L. J. & Fogo, A. B. PAI-1 and kidney fibrosis. Front. Biosci. 14, 2028\u20132041 (2009).","journal-title":"Front. Biosci."},{"key":"BFnrendo2009263_CR51","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R Rocha","year":"2002","unstructured":"Rocha, R. et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802\u2013H1810 (2002).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrendo2009263_CR52","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi, E. R. et al. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791\u20131800 (2003).","journal-title":"Kidney Int."},{"key":"BFnrendo2009263_CR53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ajh.2008.327","volume":"22","author":"TA Kotchen","year":"2009","unstructured":"Kotchen, T. A., Kotchen, J. M., Grim, C. E., Krishnaswami, S. & Kidambi, S. Aldosterone and alterations of hypertension-related vascular function in African Americans. Am. J. Hypertens. 22, 319\u2013324 (2009).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR54","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/01.ATV.0000258414.59393.89","volume":"27","author":"IZ Jaffe","year":"2007","unstructured":"Jaffe, I. Z., Tintut, Y., Newfell, B. G., Demer, L. L. & Mendelsohn, M. E. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler. Thromb. Vasc. Biol. 27, 799\u2013805 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrendo2009263_CR55","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1210\/endo.138.8.5326","volume":"138","author":"CE Gomez-Sanchez","year":"1997","unstructured":"Gomez-Sanchez, C. E. et al. Aldosterone biosynthesis in the rat brain. Endocrinology 138, 3369\u20133373 (1997).","journal-title":"Endocrinology"},{"key":"BFnrendo2009263_CR56","doi-asserted-by":"publisher","first-page":"F559","DOI":"10.1152\/ajprenal.90399.2008","volume":"297","author":"JC Geerling","year":"2009","unstructured":"Geerling, J. C. & Loewy, A. D. Aldosterone in the brain. Am. J. Physiol. Renal Physiol. 297, F559\u2013F576 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrendo2009263_CR57","doi-asserted-by":"publisher","first-page":"H517","DOI":"10.1152\/ajpheart.00651.2004","volume":"288","author":"BS Huang","year":"2005","unstructured":"Huang, B. S., Wang, H. & Leenen, F. H. Chronic central infusion of aldosterone leads to sympathetic hyperreactivity and hypertension in Dahl S but not Dahl R rats. Am. J. Physiol. Heart Circ. Physiol. 288, H517\u2013H524 (2005).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrendo2009263_CR58","doi-asserted-by":"publisher","first-page":"R699","DOI":"10.1152\/ajpregu.00041.2009","volume":"297","author":"Y Minoura","year":"2009","unstructured":"Minoura, Y., Onimaru, H., Iigaya, K., Homma, I. & Kobayashi, Y. Eectrophysiologic responses of sympathetic preganglionic neurons to angiotensin II and aldosterone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R699\u2013R706 (2009).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"BFnrendo2009263_CR59","doi-asserted-by":"publisher","first-page":"H1109","DOI":"10.1152\/ajpheart.00024.2006","volume":"291","author":"BS Huang","year":"2006","unstructured":"Huang, B. S. et al. Activation of brain renin-angiotensin-aldosterone system by central sodium in Wistar rats. Am. J. Physiol. Heart Circ. Physiol. 291, H1109\u2013H1117 (2006).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrendo2009263_CR60","doi-asserted-by":"publisher","first-page":"R994","DOI":"10.1152\/ajpregu.90903.2008","volume":"296","author":"BS Huang","year":"2009","unstructured":"Huang, B. S., White, R. A., Jeng, A. Y. & Leenen, F. H. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R994\u2013R1000 (2009).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"BFnrendo2009263_CR61","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1210\/en.2003-0109","volume":"144","author":"P Ye","year":"2003","unstructured":"Ye, P. et al. Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 144, 3321\u20133328 (2003).","journal-title":"Endocrinology"},{"key":"BFnrendo2009263_CR62","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1046\/j.1523-1755.2000.00972.x","volume":"57","author":"RR Sakai","year":"2000","unstructured":"Sakai, R. R., McEwen, B. S., Fluharty, S. J. & Ma, L. Y. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 57, 1337\u20131345 (2000).","journal-title":"Kidney Int."},{"key":"BFnrendo2009263_CR63","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1046\/j.1440-1681.2000.03259.x","volume":"27","author":"WF Ganong","year":"2000","unstructured":"Ganong, W. F. Circumventricular organs: definition and role in the regulation of endocrine and autonomic function. Clin. Exp. Pharmacol. Physiol. 27, 422\u2013427 (2000).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"BFnrendo2009263_CR64","doi-asserted-by":"publisher","first-page":"H2241","DOI":"10.1152\/ajpheart.2001.281.5.H2241","volume":"281","author":"J Francis","year":"2001","unstructured":"Francis, J. et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am. J. Physiol. Heart Circ. Physiol. 281, H2241\u2013H2251 (2001).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrendo2009263_CR65","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1523\/JNEUROSCI.3115-05.2006","volume":"26","author":"JC Geerling","year":"2006","unstructured":"Geerling, J. C., Engeland, W. C., Kawata, M. & Loewy, A. D. Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite. J. Neurosci. 26, 411\u2013417 (2006).","journal-title":"J. Neurosci."},{"key":"BFnrendo2009263_CR66","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1161\/HYPERTENSIONAHA.109.129320","volume":"53","author":"RM Reynolds","year":"2009","unstructured":"Reynolds, R. M. et al. Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure. Hypertension 53, 932\u2013936 (2009).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR67","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/01.hjh.0000170377.00591.7e","volume":"23","author":"M Isaji","year":"2005","unstructured":"Isaji, M. et al. Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2. J. Hypertens. 23, 1149\u20131157 (2005).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR68","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1210\/jc.2001-012070","volume":"87","author":"PO Lim","year":"2002","unstructured":"Lim, P. O. et al. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J. Clin. Endocrinol. Metab. 87, 4398\u20134402 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2009263_CR69","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1291\/hypres.24.105","volume":"24","author":"Y Tsujita","year":"2001","unstructured":"Tsujita, Y. et al. Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese: the Suita Study. Hypertens. Res. 24, 105\u2013109 (2001).","journal-title":"Hypertens. Res."},{"key":"BFnrendo2009263_CR70","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1161\/01.HYP.33.2.703","volume":"33","author":"E Davies","year":"1999","unstructured":"Davies, E. et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 33, 703\u2013707 (1999).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR71","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/00004872-200310000-00012","volume":"21","author":"M Castellano","year":"2003","unstructured":"Castellano, M. et al. Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J. Hypertens. 21, 1853\u20131860 (2003).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR72","doi-asserted-by":"crossref","unstructured":"Nejatizadeh, A. et al. CYP11B2 gene haplotypes independently and in concurrence with aldosterone and aldosterone to renin ratio increase the risk of hypertension. Clin. Biochem. doi:10.1016\/j.clinbiochem.2009.09.015.","DOI":"10.1016\/j.clinbiochem.2009.09.015"},{"key":"BFnrendo2009263_CR73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/01.hjh.0000254372.88488.a9","volume":"25","author":"S Sookoian","year":"2007","unstructured":"Sookoian, S., Gianotti, T. F., Gonzalez, C. D. & Pirola, C. J. Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. J. Hypertens. 25, 5\u201313 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR74","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1161\/HYPERTENSIONAHA.107.098897","volume":"51","author":"N Makhanova","year":"2008","unstructured":"Makhanova, N., Hagaman, J., Kim, H. S. & Smithies, O. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension 51, 134\u2013140 (2008).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00004872-200201000-00017","volume":"20","author":"MP Schlaich","year":"2002","unstructured":"Schlaich, M. P. et al. Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J. Hypertens. 20, 117\u2013124 (2002).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR76","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.amjhyper.2004.12.005","volume":"18","author":"S Kathiresan","year":"2005","unstructured":"Kathiresan, S. et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am. J. Hypertens. 18, 657\u2013665 (2005).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/01.HYP.36.1.7","volume":"36","author":"TA Kotchen","year":"2000","unstructured":"Kotchen, T. A. et al. Genetic determinants of hypertension: identification of candidate phenotypes. Hypertension 36, 7\u201313 (2000).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR78","first-page":"4132","volume":"84","author":"GC Inglis","year":"1999","unstructured":"Inglis, G. C. et al. Familial pattern of corticosteroids and their metabolism in adult human subjects\u2014the Scottish Adult Twin Study. J. Clin. Endocrinol. Metab. 84, 4132\u20134137 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2009263_CR79","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","volume":"49","author":"C Newton-Cheh","year":"2007","unstructured":"Newton-Cheh, C. et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49, 846\u2013856 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR80","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam, K. K. et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch. Intern. Med. 168, 1159\u20131164 (2008).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2009263_CR81","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2265.2006.02709.x","volume":"66","author":"L Lin","year":"2007","unstructured":"Lin, L. et al. Severe loss-of-function mutations in the adrenocorticotropin receptor (ACTHR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia. Clin. Endocrinol. (Oxf.) 66, 205\u2013210 (2007).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"Suppl.","key":"BFnrendo2009263_CR82","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1093\/ajcn\/65.2.612S","volume":"65","author":"FC Luft","year":"1997","unstructured":"Luft, F. C. & Weinberger, M. H. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Am. J. Clin. Nutr. 65 (Suppl.), S612\u2013S617 (1997).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnrendo2009263_CR83","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2350-6-4","volume":"6","author":"T Hannila-Handelberg","year":"2005","unstructured":"Hannila-Handelberg, T. et al. Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Med. Genet. 6, 4 (2005).","journal-title":"BMC Med. Genet."},{"key":"BFnrendo2009263_CR84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0092-8674(94)90250-X","volume":"79","author":"RA Shimkets","year":"1994","unstructured":"Shimkets, R. A. et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79, 407\u2013414 (1994).","journal-title":"Cell"},{"key":"BFnrendo2009263_CR85","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1111\/j.1523-1755.2005.00672.x","volume":"68","author":"F von Wowern","year":"2005","unstructured":"von Wowern, F. et al. Genetic variance of SGK-1 is associated with blood pressure, blood pressure change over time and strength of the insulin-diastolic blood pressure relationship. Kidney Int. 68, 2164\u20132172 (2005).","journal-title":"Kidney Int."},{"key":"BFnrendo2009263_CR86","doi-asserted-by":"crossref","first-page":"57","DOI":"10.20452\/pamw.79","volume":"117","author":"EJ Kucharz","year":"2007","unstructured":"Kucharz, E. J. Michal Litynski\u2014a forgotten author of the first description on primary hyperaldosteronism [Polish]. Pol. Arch. Med. Wewn. 117, 57\u201358 (2007).","journal-title":"Pol. Arch. Med. Wewn."},{"key":"BFnrendo2009263_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-44-1-1","volume":"44","author":"JW Conn","year":"1956","unstructured":"Conn, J. W. & Louis, L. H. Primary aldosteronism, a new clinical entity. Ann. Intern. Med. 44, 1\u201315 (1956).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2009263_CR88","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.123.3195.503","volume":"123","author":"J Genest","year":"1956","unstructured":"Genest, J. et al. Human arterial hypertension: a state of mild chronic hyperaldosteronism? Science 123, 503\u2013505 (1956).","journal-title":"Science"},{"key":"BFnrendo2009263_CR89","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0002-9343(73)90082-X","volume":"54","author":"RP Russell","year":"1973","unstructured":"Russell, R. P. & Masi, A. T. Significant associations of adrenal cortical abnormalities with \u201cessential\u201d hypertension. Am. J. Med. 54, 44\u201351 (1973).","journal-title":"Am. J. Med."},{"key":"BFnrendo2009263_CR90","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L Mosso","year":"2003","unstructured":"Mosso, L. et al. Primary aldosteronism and hypertensive disease. Hypertension 42, 161\u2013165 (2003).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-6823-9-11","volume":"9","author":"S Pilz","year":"2009","unstructured":"Pilz, S. et al. Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr. Disord. 9, 11 (2009).","journal-title":"BMC Endocr. Disord."},{"key":"BFnrendo2009263_CR92","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B. & Weissmann, P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40, 892\u2013896 (2002).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR93","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/HYPERTENSIONAHA.106.086116","volume":"50","author":"DA Calhoun","year":"2007","unstructured":"Calhoun, D. A. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension 50, 447\u2013453 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR94","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1161\/HYPERTENSIONAHA.106.086124","volume":"50","author":"NM Kaplan","year":"2007","unstructured":"Kaplan, N. M. Is there an unrecognized epidemic of primary aldosteronism? Con. Hypertension 50, 454\u2013458 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR95","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1046\/j.1440-1681.2001.03585.x","volume":"28","author":"B Fiquet-Kempf","year":"2001","unstructured":"Fiquet-Kempf, B., Launay-Mignot, P., Bobrie, G. & Plouin, P. F. Is primary aldosteronism underdiagnosed in clinical practice? Clin. Exp. Pharmacol. Physiol. 28, 1083\u20131086 (2001).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"BFnrendo2009263_CR96","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","volume":"19","author":"M Sartori","year":"2006","unstructured":"Sartori, M. et al. Aldosterone and refractory hypertension: a prospective cohort study. Am. J. Hypertens. 19, 373\u2013379 (2006).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR97","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/jhh.2008.27","volume":"22","author":"P Meneton","year":"2008","unstructured":"Meneton, P. et al. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations. J. Hum. Hypertens. 22, 550\u2013558 (2008).","journal-title":"J. Hum. Hypertens."},{"key":"BFnrendo2009263_CR98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.108.816108","volume":"119","author":"W Lieb","year":"2009","unstructured":"Lieb, W. et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation 119, 37\u201343 (2009).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR99","first-page":"P9","volume":"16","author":"A Tomaschitz","year":"2008","unstructured":"Tomaschitz, A. et al. How does the aldosterone renin ratio impact blood pressure levels? A cross-sectional study of 3056 normo- and hypertensive patients referred to coronary angiography. Endocrine Abstracts 16, P9 (2008).","journal-title":"Endocrine Abstracts"},{"key":"BFnrendo2009263_CR100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00004872-200201000-00003","volume":"20","author":"PO Lim","year":"2002","unstructured":"Lim, P. O., Struthers, A. D. & MacDonald, T. M. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J. Hypertens. 20, 11\u201315 (2002).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR101","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"IK Eide","year":"2004","unstructured":"Eide, I. K., Torjesen, P. A., Drolsum, A., Babovic, A. & Lilledahl, N. P. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens. 22, 2217\u20132226 (2004).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR102","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/01.HYP.35.3.694","volume":"35","author":"P Mulatero","year":"2000","unstructured":"Mulatero, P. et al. CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 35, 694\u2013698 (2000).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR103","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/00045415-200008040-00005","volume":"8","author":"JH Pratt","year":"2000","unstructured":"Pratt, J. H. Low-renin hypertension: more common than we think? Cardiol. Rev. 8, 202\u2013206 (2000).","journal-title":"Cardiol. Rev."},{"key":"BFnrendo2009263_CR104","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1097\/HJH.0b013e3282a9be30","volume":"25","author":"E Pimenta","year":"2007","unstructured":"Pimenta, E. et al. Aldosterone excess and resistance to 24-h blood pressure control. J. Hypertens. 25, 2131\u20132137 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2265.2008.03498.x","volume":"71","author":"G Lastra-Lastra","year":"2009","unstructured":"Lastra-Lastra, G., Sowers, J. R., Restrepo-Erazo, K., Manrique-Acevedo, C. & Lastra-Gonzalez, G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin. Endocrinol. (Oxf.) 71, 1\u20136 (2009).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2009263_CR106","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/HYPERTENSIONAHA.107.093955","volume":"50","author":"H Hitomi","year":"2007","unstructured":"Hitomi, H. et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50, 750\u2013755 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR107","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1097\/HJH.0b013e3282861fa4","volume":"25","author":"LM Mosso","year":"2007","unstructured":"Mosso, L. M. et al. A possible association between primary aldosteronism and a lower beta-cell function. J. Hypertens. 25, 2125\u20132130 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR108","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M Bochud","year":"2006","unstructured":"Bochud, M. et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48, 239\u2013245 (2006).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR109","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","volume":"43","author":"TL Goodfriend","year":"2004","unstructured":"Goodfriend, T. L. & Calhoun, D. A. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43, 518\u2013524 (2004).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR110","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","volume":"150","author":"JR Sowers","year":"2009","unstructured":"Sowers, J. R., Whaley-Connell, A. & Epstein, M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 150, 776\u2013783 (2009).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo2009263_CR111","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/00365517809108418","volume":"38","author":"K Tolagen","year":"1978","unstructured":"Tolagen, K. & Karlberg, B. E. Plasma and urinary aldosterone and their interrelations with blood pressure, plasma renin activity and urinary electrolytes in normotensive subjects. Scand. J. Clin. Lab. Invest. 38, 241\u2013247 (1978).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"BFnrendo2009263_CR112","doi-asserted-by":"publisher","first-page":"17A","DOI":"10.1016\/0002-9149(93)90240-D","volume":"71","author":"DA Duprez","year":"1993","unstructured":"Duprez, D. A. et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am. J. Cardiol. 71, 17A\u201320A (1993).","journal-title":"Am. J. Cardiol."},{"key":"BFnrendo2009263_CR113","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1161\/01.HYP.1.3.287","volume":"1","author":"WG Walker","year":"1979","unstructured":"Walker, W. G., Whelton, P. K., Saito, H., Russell, R. P. & Hermann, J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1, 287\u2013291 (1979).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR114","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/01.HYP.0000154364.00763.d5","volume":"45","author":"CE Grim","year":"2005","unstructured":"Grim, C. E. et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension 45, 766\u2013772 (2005).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR115","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.108.117531","volume":"52","author":"A Di Zhang","year":"2008","unstructured":"Di Zhang, A. et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52, 1060\u20131067 (2008).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR116","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","volume":"40","author":"A Virdis","year":"2002","unstructured":"Virdis, A. et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40, 504\u2013510 (2002).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR117","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/ki.2009.9","volume":"75","author":"WB Lea","year":"2009","unstructured":"Lea, W. B. et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75, 936\u2013944 (2009).","journal-title":"Kidney Int."},{"key":"BFnrendo2009263_CR118","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00109-008-0343-1","volume":"86","author":"T Fujita","year":"2008","unstructured":"Fujita, T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J. Mol. Med. 86, 729\u2013734 (2008).","journal-title":"J. Mol. Med."},{"key":"BFnrendo2009263_CR119","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jama.1974.03230180016005","volume":"227","author":"JG Douglas","year":"1974","unstructured":"Douglas, J. G., Hollifield, J. W. & Liddle, G. W. Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination. JAMA 227, 518\u2013521 (1974).","journal-title":"JAMA"},{"key":"BFnrendo2009263_CR120","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","volume":"116","author":"SJ Hood","year":"2007","unstructured":"Hood, S. J., Taylor, K. P., Ashby, M. J. & Brown, M. J. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 116, 268\u2013275 (2007).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR121","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka, M. K., Zaman, M. A. & Calhoun, D. A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16, 925\u2013930 (2003).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR122","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane, D. A., Shah, S. & Beevers, D. G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J. Hypertens. 25, 891\u2013894 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR123","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman, N. et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49, 839\u2013845 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR124","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","volume":"46","author":"E Gross","year":"2005","unstructured":"Gross, E., Rothstein, M., Dombek, S. & Juknis, H. I. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am. J. Kidney Dis. 46, 94\u2013101 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrendo2009263_CR125","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","volume":"6","author":"T Saruta","year":"2004","unstructured":"Saruta, T. et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J. Clin. Hypertens. (Greenwich) 6, 175\u2013185 (2004).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"BFnrendo2009263_CR126","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger, M. H., Roniker, B., Krause, S. L. & Weiss, R. J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15, 709\u2013716 (2002).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR127","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White, W. B. et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41, 1021\u20131026 (2003).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR128","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt, B. et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108, 1831\u20131838 (2003).","journal-title":"Circulation"},{"key":"BFnrendo2009263_CR129","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"MH Weinberger","year":"2005","unstructured":"Weinberger, M. H. et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am. Heart J. 150, 426\u2013433 (2005).","journal-title":"Am. Heart J."},{"key":"BFnrendo2009263_CR130","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack, J. M. et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 41, 1148\u20131155 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrendo2009263_CR131","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum, H. et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40, 117\u2013123 (2002).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR132","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/HYPERTENSIONAHA.107.104299","volume":"51","author":"T Imanishi","year":"2008","unstructured":"Imanishi, T. et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 51, 734\u2013741 (2008).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR133","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","volume":"48","author":"PO Lim","year":"1999","unstructured":"Lim, P. O., Jung, R. T. & MacDonald, T. M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br. J. Clin. Pharmacol. 48, 756\u2013760 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrendo2009263_CR134","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1177\/0091270003258189","volume":"43","author":"LM Prisant","year":"2003","unstructured":"Prisant, L. M. et al. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J. Clin. Pharmacol. 43, 1203\u20131210 (2003).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrendo2009263_CR135","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","volume":"18","author":"A Mahmud","year":"2005","unstructured":"Mahmud, A., Mahgoub, M., Hall, M. & Feely, J. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am. J. Hypertens. 18, 1631\u20131635 (2005).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR136","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11906-004-0051-3","volume":"6","author":"MH Weinberger","year":"2004","unstructured":"Weinberger, M. H. The use of selective aldosterone antagonists. Curr. Hypertens. Rep. 6, 342\u2013345 (2004).","journal-title":"Curr. Hypertens. Rep."},{"key":"BFnrendo2009263_CR137","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1517\/14656566.5.12.2573","volume":"5","author":"E Burgess","year":"2004","unstructured":"Burgess, E. Eplerenone in hypertension. Expert Opin. Pharmacother. 5, 2573\u20132581 (2004).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrendo2009263_CR138","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","volume":"27","author":"PM Jansen","year":"2009","unstructured":"Jansen, P. M., Danser, A. H., Imholz, B. P. & van den Meiracker, A. H. Aldosterone-receptor antagonism in hypertension. J. Hypertens. 27, 680\u2013691 (2009).","journal-title":"J. Hypertens."},{"key":"BFnrendo2009263_CR139","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543\u2013551 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2009263_CR140","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","volume":"46","author":"C Saha","year":"2005","unstructured":"Saha, C. et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46, 481\u2013487 (2005).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR141","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/hy1101.095010","volume":"38","author":"JH Pratt","year":"2001","unstructured":"Pratt, J. H., Eckert, G. J., Newman, S. & Ambrosius, W. T. Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects. Hypertension 38, 1124\u20131129 (2001).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR142","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/jcp.1041610203","volume":"161","author":"ME Ullian","year":"1994","unstructured":"Ullian, M. E. & Fine, J. J. Mechanisms of enhanced angiotensin II-stimulated signal transduction in vascular smooth muscle by aldosterone. J. Cell. Physiol. 161, 201\u2013208 (1994).","journal-title":"J. Cell. Physiol."},{"key":"BFnrendo2009263_CR143","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1161\/01.HYP.0000123572.45556.a5","volume":"43","author":"H Oberleithner","year":"2004","unstructured":"Oberleithner, H. et al. Human endothelium: target for aldosterone. Hypertension 43, 952\u2013956 (2004).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR144","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","volume":"49","author":"S Kidambi","year":"2007","unstructured":"Kidambi, S. et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49, 704\u2013711 (2007).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR145","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/S0895-7061(99)00128-4","volume":"12","author":"H Schunkert","year":"1999","unstructured":"Schunkert, H., Hense, H. W., Andus, T., Riegger, G. A. & Straub, R. H. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. Am. J. Hypertens. 12, 1140\u20131143 (1999).","journal-title":"Am. J. Hypertens."},{"key":"BFnrendo2009263_CR146","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/01.HYP.37.3.845","volume":"37","author":"AH El-Gharbawy","year":"2001","unstructured":"El-Gharbawy, A. H. et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37, 845\u2013850 (2001).","journal-title":"Hypertension"},{"key":"BFnrendo2009263_CR147","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.0954-6820.1982.tb01961.x","volume":"211","author":"S Ljungman","year":"1982","unstructured":"Ljungman, S., Aurell, M., Hartford, M., Wikstrand, J. & Berglund, G. Blood pressure in relation to the renin-angiotensin-aldosterone system. Acta Med. Scand. 211, 351\u2013360 (1982).","journal-title":"Acta Med. Scand."},{"key":"BFnrendo2009263_CR148","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjhyper.2004.08.025","volume":"18","author":"M Lamarre-Cliche","year":"2005","unstructured":"Lamarre-Cliche, M. et al. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am. J. Hypertens. 18, 56\u201364 (2005).","journal-title":"Am. J. Hypertens."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2009.263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2009.263","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2009.263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T18:15:56Z","timestamp":1739470556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2009.263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,22]]},"references-count":148,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["BFnrendo2009263"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2009.263","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,22]]}}}